Literature DB >> 25525795

HIV-1 integrase variants retarget viral integration and are associated with disease progression in a chronic infection cohort.

Jonas Demeulemeester1, Sofie Vets2, Rik Schrijvers2, Paradise Madlala3, Marc De Maeyer4, Jan De Rijck2, Thumbi Ndung'u5, Zeger Debyser6, Rik Gijsbers7.   

Abstract

Distinct integration patterns of different retroviruses, including HIV-1, have puzzled virologists for over 20 years. A tetramer of the viral integrase (IN) assembles on the two viral cDNA ends, docks onto the target DNA (tDNA), and catalyzes viral genome insertion into the host chromatin. We identified the amino acids in HIV-1 IN that directly contact tDNA bases and affect local integration site sequence selection. These residues also determine the propensity of the virus to integrate into flexible tDNA sequences. Remarkably, natural polymorphisms INS119G and INR231G retarget viral integration away from gene-dense regions. Precisely these variants were associated with rapid disease progression in a chronic HIV-1 subtype C infection cohort. These findings link integration site selection to virulence and viral evolution, but also to the host immune response and antiretroviral therapy, since HIV-1 IN119 is under selection by HLA alleles and integrase inhibitors.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25525795     DOI: 10.1016/j.chom.2014.09.016

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  25 in total

1.  Amplification, Next-generation Sequencing, and Genomic DNA Mapping of Retroviral Integration Sites.

Authors:  Erik Serrao; Peter Cherepanov; Alan N Engelman
Journal:  J Vis Exp       Date:  2016-03-22       Impact factor: 1.355

Review 2.  Nuclear landscape of HIV-1 infection and integration.

Authors:  Marina Lusic; Robert F Siliciano
Journal:  Nat Rev Microbiol       Date:  2016-12-12       Impact factor: 60.633

3.  Key determinants of target DNA recognition by retroviral intasomes.

Authors:  Erik Serrao; Allison Ballandras-Colas; Peter Cherepanov; Goedele N Maertens; Alan N Engelman
Journal:  Retrovirology       Date:  2015-04-30       Impact factor: 4.602

4.  Capsid-CPSF6 Interaction Is Dispensable for HIV-1 Replication in Primary Cells but Is Selected during Virus Passage In Vivo.

Authors:  Akatsuki Saito; Matthew S Henning; Erik Serrao; Brittany N Dubose; Samantha Teng; Jing Huang; Xiangming Li; Namiko Saito; Saumendra Prasad Roy; Mohammad Adnan Siddiqui; Jinwoo Ahn; Moriya Tsuji; Theodora Hatziioannou; Alan N Engelman; Masahiro Yamashita
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

Review 5.  What Integration Sites Tell Us about HIV Persistence.

Authors:  Stephen H Hughes; John M Coffin
Journal:  Cell Host Microbe       Date:  2016-05-11       Impact factor: 21.023

Review 6.  Cellular and molecular mechanisms of HIV-1 integration targeting.

Authors:  Alan N Engelman; Parmit K Singh
Journal:  Cell Mol Life Sci       Date:  2018-02-07       Impact factor: 9.261

Review 7.  Sites of retroviral DNA integration: From basic research to clinical applications.

Authors:  Erik Serrao; Alan N Engelman
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-10-28       Impact factor: 8.250

Review 8.  Structure and function of retroviral integrase.

Authors:  Goedele N Maertens; Alan N Engelman; Peter Cherepanov
Journal:  Nat Rev Microbiol       Date:  2021-07-09       Impact factor: 60.633

9.  Vulnerable targets in HIV-1 Pol for attenuation-based vaccine design.

Authors:  Doty B A Ojwach; Paradise Madlala; Michelle Gordon; Thumbi Ndung'u; Jaclyn K Mann
Journal:  Virology       Date:  2020-12-10       Impact factor: 3.616

10.  Structural and sequencing analysis of local target DNA recognition by MLV integrase.

Authors:  Sriram Aiyer; Paolo Rossi; Nirav Malani; William M Schneider; Ashwin Chandar; Frederic D Bushman; Gaetano T Montelione; Monica J Roth
Journal:  Nucleic Acids Res       Date:  2015-05-12       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.